Prof. Dr. Fangfang Tao | Chikungunya Virus | Best Researcher Award
Zhejiang Chinese Medical University | China
Prof. Dr. Fangfang Tao is a dedicated researcher at Zhejiang Chinese Medical University whose work spans integrative medicine, public health, and translational biomedical science. With a portfolio of 35 peer-reviewed publications and over 380 citations, Dr. Tao has established a growing scholarly presence supported by an h-index of 11, reflecting consistent influence and research quality. Her contributions often integrate traditional Chinese medical principles with modern clinical and epidemiological approaches, advancing evidence-based understanding of disease mechanisms, therapeutic strategies, and patient-centered health outcomes. Dr. Tao’s collaborative record is extensive, with partnerships involving more than 100 co-authors across national and international institutions, demonstrating her commitment to interdisciplinary inquiry and global scientific engagement. Her work contributes meaningfully to emerging health challenges by prioritizing rigorous methodology, culturally relevant medical insights, and innovative therapeutic frameworks. Through her research, Dr. Tao aims to bridge traditional medical knowledge with contemporary biomedical science to enhance clinical practice, inform health policy, and promote accessible, effective care. Her scholarly achievements underscore not only a strong trajectory in academic research but also a broader societal impact, as her studies support improved diagnostic approaches, better-targeted interventions, and enhanced patient well-being across diverse populations.
Featured Publications
1. Niu, N., Zhang, J., Zhang, N., Mercado-Uribe, I., Tao, F., Han, Z., Pathak, S., … (2016). Linking genomic reorganization to tumor initiation via the giant cell cycle. Oncogenesis, 5(12), e281.
Cited by: 169
2. Tao, F., Tian, X., Ruan, S., Shen, M., & Zhang, Z. (2018). miR‐211 sponges lncRNA MALAT1 to suppress tumor growth and progression through inhibiting PHF19 in ovarian carcinoma. The FASEB Journal, 32(11), 6330–6343.
Cited by: 92
3. Tao, F., Tian, X., Lu, M., & Zhang, Z. (2018). A novel lncRNA, Lnc-OC1, promotes ovarian cancer cell proliferation and migration by sponging miR-34a and miR-34c. Journal of Genetics and Genomics, 45(3), 137–145.
Cited by: 59
4. Tian, X., Tao, F., Zhang, B., Dong, J. T., & Zhang, Z. (2018). The miR‐203/SNAI2 axis regulates prostate tumor growth, migration, angiogenesis and stemness potentially by modulating GSK‐3β/β-catenin signal pathway. IUBMB Life, 70(3), 224–236.
Cited by: 42
5. Jiang, X., Cui, X., Xu, H., Liu, W., Tao, F., Shao, T., Pan, X., & Zheng, B. (2019). Whole genome sequencing of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolated from a wastewater treatment plant in China. Frontiers in Microbiology, 10, 1797.
Cited by: 34
Prof. Dr. Fangfang Tao’s work advances molecular oncology by uncovering RNA-mediated regulatory pathways that drive cancer development and progression. Her research contributes to more precise diagnostic biomarkers and innovative therapeutic strategies, supporting global efforts to reduce the burden of cancer.